Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-aminopyridine versus placebo for freezing of gait in Parkinson's disease
IRCT20251122068081N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of dalfampridine in Parkinson's disease (PD) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Severity of freezing of gait, Frequency of freezing of gait episodes and 1 more. Started Dec 2025; status: completed.
02
Drugs
dalfampridine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on IRCT20251122068081N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251122068081N2.